Stem Cell Banking Market Analysis Focusing on the Key Issues Surrounding the Growth of the Industry and Further Develop Opportunities – Bandera County…

Stem Cell Banking market gives us the acute prediction regarding sales and trends:The current report focuses on the impact of Covid-19 on Stem Cell Banking market industry. This report covers all the important areas like how the key players are enhancing their activities for their survival in the worldwide Stem Cell Banking market business. Graphs and flowcharts are being used for analyzing the information to be acceptable.

Key player focused on this market are: CCBC, CBR, Esperite, Vcanbio, Boyalife, LifeCell, Crioestaminal, RMSRegrow, CordlifeGroup, ViaCord, PBKMFamiCord, cells4life, Beikebiotech, StemCyte, Cryo-cell, CellsafeBiotechGroup, PacifiCord, Americord, Krio, Familycord, CryoStemcell, StemadeBiotech

Download Special samples With the effect of COVID19@: https://www.regalintelligence.com/request-covid19-global-insights/17354

Stem Cell Banking research study depicts the constantly changing trends and growth in the market with valued CAGR (compounded annual growth rate) in their forecast including all the factors responsible for the changed performance, growth evaluation and profitability in the market business.

Key points on which report focuses are:

Providing acute information.

Professional study for the period 2020-2024.

Details of upstream raw materials, downstream demand and production value.

Market growth factors.

Market segmentation:

Basis of segmentation: Types of products, application and region.

By Type: UmbilicalCordBloodStemCell, EmbryonicStemCell, AdultStemCell,

Significant Stem Cell Banking application along with their consumption details: DiseasesTherapy, Healthcare,

The time period to estimate the market size:

The history year 2015-2019

The base year 2019

Estimated 2020

Forecast 2020-2024

Segmentation is concerned with the market share, revenue and growth rate etc. The report shows the high growth period of Stem Cell Banking markets and how can the segments grow during the forecast period.

Ask For Discount@ https://www.regalintelligence.com/check-discount/17354

The main objective of Stem Cell Banking market report is future forecasting, determining opportunities, challenges and threats, making suitable business plans, analyzing market competition and getting advantages and helps in decision making.

This report answers to questions like: Growth rate and market size in 2024.

Effecting factors, opportunities, challenges, threats of the global Stem Cell Banking market. Competing products.

What M&A activity has taken place in past years.

Table of Contents:

Chapter 1 About the Stem Cell Banking Industry

1.1 Industry Definition and Types

1.2 Main Market Activities

1.3 Similar Industries

1.4 Industry at a Glance

Chapter 2 World Market Competition Landscape

2.1 Stem Cell Banking Markets by Regions

Market Revenue (M USD) and Growth Rate 2015-2024

Sales and Growth Rate 2015-2024

Major Players Revenue (M USD) in 2020

2.2 World Stem Cell Banking Market by Types

2.3 World Stem Cell Banking Market by Applications

2.4 World Stem Cell Banking Market Analysis

2.4.1 World Stem Cell Banking Market Revenue and Growth Rate 2015-2020

2.4.2 World Stem Cell Banking Market Consumption and Growth rate 2015-2020

2.4.3 World Stem Cell Banking Market Price Analysis 2015-2020

Chapter 3 World Stem Cell Banking Market share

3.1 Major Production Market share by Players

3.2 Major Revenue (M USD) Market share by Players

3.3 Major Production Market share by Regions in 2020, Through 2024

3.4 Major Revenue (M USD) Market share By Regions in 2020, Through 2024

Chapter 4 Supply Chain Analysis

4.1 Industry Supply chain Analysis

4.2 Raw material Market Analysis

4.2.1 Raw material Prices Analysis 2015-2020

4.2.2 Raw material Supply Market Analysis

4.2 Manufacturing Equipment Suppliers Analysis

4.3 Production Process Analysis

4.4 Production Cost Structure Benchmarks

4.5 End users Market Analysis

Get Full Report@ https://www.regalintelligence.com/buyNow/17354

Conclusion: This report covers all the necessary information like market landscapes production and consumption analysis, demand and supply analysis, market growth analysis with future predictions and SWOT and PEST analysis, investment and return analysis.

Visit link:
Stem Cell Banking Market Analysis Focusing on the Key Issues Surrounding the Growth of the Industry and Further Develop Opportunities - Bandera County...

QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS) – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation, a biotech company focused on developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced the raise of a $42 million Series A financing, bringing the total funds raised to $50.5 million. The financing was led by LS Polaris Innovation Fund, lead seed investor Mission BioCapital, INKEF Capital and the Dementia Discovery Fund, and co-led by Droia Ventures. Additional new investors include Mitsui Global Investment and Dolby Family Ventures, joined by investments from existing investors Amgen Ventures, MP Healthcare Venture Management, and Sanford Biosciences. QurAlis intends to use this funding to support the development of new therapies for ALS and genetically related frontotemporal dementia (FTD), neurodegenerative diseases for which there is currently no cure.

This Series A funding will allow us to take the next major step in our growth and advance our lead programs into the clinic. Recent advances in science and technology have identified strong disease targets for specific groups of ALS and FTD patients. Combined with our proprietary human stem cell technologies and development capabilities, we believe we are placed in a very good position to bring forth real treatments, said Kasper Roet, Ph.D., Chief Executive Officer of QurAlis. The QurAlis team built this company from the ground up on a foundation of cutting-edge science and profound dedication to helping ALS patients above all else. The great support of our existing and new investors from the US, Europe and Japan underscores the international nature of our mission. We plan to use this funding to continue advancing ALS and FTD therapies for patients around the world who are in critical need of effective treatments.

As ALS can be caused by mutations in over 25 individual human genes, many of which also cause FTD, QurAlis strategy is to systematically investigate treatments targeting specific disease-causing mechanisms in patient sub-populations. The company evaluates a wide range of potential treatments through the companys transformative system that utilizes lab-grown neuronal networks derived from cells of ALS patients.

Between the companys strong scientific foundation and support by ALS luminaries Kevin Eggan and his co-founders, promising pipeline of potential ALS treatments, and its dedicated team of experts in the field of neurologic therapeutics, QurAlis is very well positioned to make a tremendous difference for patients with ALS and FTD, said Amy Schulman, Managing Partner of the LS Polaris Innovation Fund. We are proud to support their mission and have deep faith in their transformative technology, which has already supported the discovery of several promising ALS candidate therapeutics.

In connection with the financing round, Amy Schulman, Managing Partner of the LS Polaris Innovation Fund; Roel Bulthuis, Managing Partner at INKEF Capital; Jonathan Behr, Ph.D., Partner at the Dementia Discovery Fund; and Luc Dochez, Managing Partner at DROIA Ventures, will be joining Johannes Fruehauf, M.D., Ph.D., General Partner at Mission BioCapital, on QurAlis Board.

About ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease, is a progressive neurodegenerative disease impacting nerve cells in the brain and spinal cord. ALS breaks down nerve cells, reducing muscle function and causing loss of muscle control. ALS can be traced to mutations in over 25 different genes and is often caused by a combination of multiple sub-forms of the condition. Its average life expectancy is three years, and there is currently no cure for the disease.

About QurAlis Corporation

QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms.

Link:
QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS) - Business Wire

Stem Cell Therapy | Global Industry Review 2015-2019 and Forecast to 2025 – PRNewswire

DUBLIN, May 13, 2020 /PRNewswire/ -- The "Global Stem Cell Therapy Market By Type (Allogeneic, Autologous, Syngeneic), By Source of Stem Cells (Adipose Tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs, Others), By Application, By End Users, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Stem Cell Therapy Market is expected to grow at a formidable rate of around 12% during the forecast period. The industry is segmented based on type, source of stem cells, application, end-users, company and region.

The market is driven by the growing popularity and awareness pertaining to the use of stem cells for the prevention and cure of certain life threatening diseases. Additionally, increase in number of stem cell banks and growing investments by the government and private organizations for the development of stem cell preservation infrastructure is further propelling the market across the globe.

Based on type, the market can be categorized into allogeneic, autologous and syngeneic. The allogenic type segment is expected to register the highest growth during forecast period attributable to the rising commercialization of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easy production scale-up process, growing number of clinical trials related to allogeneic stem cell therapies, among others.

Based on end-users, the market can be bifurcated into hospitals and clinics. The hospitals segment is expected to dominate the market during the forecast years. This can be accredited to the rising preference for stem cell therapies offered by hospitals proves beneficial for the business growth. Hospitals have affiliations with research laboratories and academic institutes that carry out research activities for developing stem cell therapies. On introduction and approval of any novel stem therapy, hospitals implement it immediately.

Regionally, the stem cell therapy market has been segmented into various regions namely Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these regions, North America is expected to dominate the overall stem cell therapy market during the next five years on account of the increasing number of clinical trials for stem cell-based products and increasing public-private funding & research grants.

Major players operating in the Global Stem Cell Therapy Market include Osiris Therapeutics, Inc., MEDIPOST Co., Ltd., Anterogen Co., Ltd., Pharmicell Co., Ltd., Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals Co., Ltd., NuVasive, Inc., RTI Surgical, Inc., AlloSource, Thermo Fisher Scientific and others. The companies are developing advanced technologies and launching new services in order to stay competitive in the market.

Years considered for this report:

Objective of the Study

Key Topics Covered

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Stem Cell Therapy Market Outlook5.1. Market Size & Forecast5.1.1. By Value5.2. Market Share & Forecast5.2.1. By Type (Allogeneic, Autologous, Syngeneic)5.2.2. By Source of Stem Cells (Adipose Tissue, Bone Marrow, Neural, Embryo/Cord Blood Derived, iPSCs, Others)5.2.3. By Application (Musculoskeletal, Wound & Injury, Cardiovascular Disease (CVD), Surgery, Acute Graft-Versus-Host Disease, Drug Discovery & Development, Others)5.2.4. By End Users (Hospitals v/s Clinics)5.2.5. By Company (2019)5.2.6. By Region5.3. Product Market Map

6. Asia-Pacific Stem Cell Therapy Market Outlook

7. Europe Stem Cell Therapy Market Outlook

8. North America Stem Cell Therapy Market Outlook

9. South America Stem Cell Therapy Market Outlook

10. Middle East and Africa Stem Cell Therapy Market Outlook11. Market Dynamics11.1. Drivers11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape13.1. Osiris Therapeutics, Inc.13.2. MEDIPOST Co. Ltd.13.3. Anterogen Co. Ltd.13.4. Pharmicell Co. Ltd.13.5. Holostem Terapie Avanzate S.r.l.13.6. JCR Pharmaceuticals Co. Ltd.13.7. NuVasive, Inc.13.8. RTI Surgical, Inc.13.9. AlloSource13.10. Thermo Fisher Scientific

14. Strategic Recommendations

For more information about this report visit https://www.researchandmarkets.com/r/j7namd

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the original post:
Stem Cell Therapy | Global Industry Review 2015-2019 and Forecast to 2025 - PRNewswire

Umbilical Cord Stem Cell Therapy to Be Assessed in Severe COVID-19 – Monthly Prescribing Reference

The Food and Drug Administration (FDA) has approved a phase 1/2a study evaluating the use of umbilical cord mesenchymal stem cells for the treatment of patients with severe cases of coronavirus disease 2019 (COVID-19).

The multicenter, randomized, blinded, placebo-controlled SUCCESS (Systemic Umbilical Cord Cells to Ease Severe Syndrome) study will assess the efficacy and safety of umbilical cord mesenchymal stem cells provided by RESTEM, a cell-based therapeutics company, in hospitalized patients with severe COVID-19 (N=60). RESTEMs cells are grown from umbilical cord tissue through a proprietary process that rapidly replicates millions of doses.

The SUCCESS study will identify COVID-19 patients with acute respiratory distress syndrome (ARDS) who would best benefit from the therapy. Patient enrollment is expected to begin this week from Baptist Health South Florida and Sanford Health.

We are excited to launch this study and demonstrate the potential of our patented umbilical cord lining stem cell (ULSC) technology, said Dr. Rafael Gonzalez, senior vice president of research & development for RESTEM. Based on the properties of our cells and targeted treatments, our breakthrough technology has shown promise to help those suffering from COVID-19 complications.

Use of the novel therapy for COVID-19 was based on promising results in patients previously treated at the Miami Cancer Institute under the FDAs Emergency Use Authorization. Treatment with umbilical cord mesenchymal stem cells was associated with a reduction in both oxygen requirements and circulating inflammatory markers in 3 critically ill COVID-19 patients.

For more information visit sanfordhealth.org or baptisthealth.net.

Original post:
Umbilical Cord Stem Cell Therapy to Be Assessed in Severe COVID-19 - Monthly Prescribing Reference

Coronavirus: Emirati dentist who received stem cell therapy doing well – Gulf News

Emirati dentist with the officials Image Credit: Supplied

Ras Al Khaimah: An Emirati dentist, who received stem cell therapy after she got infected with coronavirus (COVID-19) due to transmission from a patient, was recently visited by Dr Mohamed Salim Al Olama, undersecretary of the Ministry of Health and Prevention (MoHAP) and head of the Board of Directors of the Emirates Health Services Corporation.

Dr Muhra Abdul Rahim Al-Awadi, who underwent the innovative stem cell therapy, is one of the current patients at Obaidullah Elderly Hospital in Ras Al Khaimah.

Dr Al Olama also made a series of field visits to determine the readiness of various hospitals and the conditions of medical cadres across the country, according to MoHAP.

He expressed his appreciation to Al-Awadis diligence and dedication to her homeland and called it as a national example of giving, loyalty, and sacrifice.

He added MoHAP is proud of its medical sector and it pays great attention to its employees health through the provision of the best methods of infection prevention.

According to MoHAP, Al-Awadi thanked Dr Al Olama for the visit, which pleased and motivated her to continue to work diligently after her full recovery.

She said at present she does not have any symptoms of fever or breathing difficulty and that she is recuperating after receiving stem cell therapy.

Originally posted here:
Coronavirus: Emirati dentist who received stem cell therapy doing well - Gulf News

Stem Cell Therapy Market Research Report 2020 By Size, Share, Trends, Analysis and Forecast to 2026 – Cole of Duty

Allosource

Stem Cell Therapy Market Competitive Analysis:

In addition, the projections offered in this report were derived using proven research assumptions and methods. In this way, the Stem Cell Therapy research study offers a collection of information and analysis for every facet of the Stem Cell Therapy market such as technology, regional markets, applications and types. The Stem Cell Therapy market report also offers some market presentations and illustrations that include pie charts, diagrams and charts that show the percentage of different strategies implemented by service providers in the Stem Cell Therapy market. In addition, the report was created using complete surveys, primary research interviews, observations and secondary research.

In addition, the Stem Cell Therapy market report introduced the market through various factors such as classifications, definitions, market overview, product specifications, cost structures, manufacturing processes, raw materials and applications. This report also provides key data on SWOT analysis, return data for investments and feasibility analysis for investments. The Stem Cell Therapy market study also highlights the extremely lucrative market opportunities that are influencing the growth of the global market. In addition, the study offers a complete analysis of market size, segmentation and market share. In addition, the Stem Cell Therapy report contains market dynamics such as market restrictions, growth drivers, opportunities, service providers, stakeholders, investors, important market participants, profile assessment and challenges of the global market.

Stem Cell Therapy Market Segments:

The report also underscores their strategics planning including mergers, acquisitions, ventures, partnerships, product launches, and brand developments. Additionally, the report renders the exhaustive analysis of crucial market segments, which includes Stem Cell Therapy types, applications, and regions. The segmentation sections cover analytical and forecast details of each segment based on their profitability, global demand, current revue, and development prospects. The report further scrutinizes diverse regions including North America, Asia Pacific, Europe, Middle East, and Africa, and South America. The report eventually helps clients in driving their Stem Cell Therapy business wisely and building superior strategies for their Stem Cell Therapy businesses.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=COD&utm_medium=003

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market, By Solution

6.1 Overview

7 Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Stem Cell Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=COD&utm_medium=003

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Analysis NMK, Majhi Naukri, Sarkari Naukri, Sarkari Result

Our Trending Reports

Metabolomics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Stem Cell Therapy Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Go here to see the original:
Stem Cell Therapy Market Research Report 2020 By Size, Share, Trends, Analysis and Forecast to 2026 - Cole of Duty

Outcomes of Hematopoietic Stem Cell Transplantation in Children With Diamond-Blackfan Anemia – Hematology Advisor

Hematopoieticstem cell transplantation (HSCT) is safe and efficient in children with Diamond-Blackfananemia (DBA), especially in the absence of a matched sibling donor (MSD) ormatched unrelated donor (UD), according to a study published in BloodAdvances.

DBAis associated with congenital anomalies and cancer predisposition. Treatmentfor DBA includes regular transfusions with chelation and corticoid therapies. Patientsthat remain transfusion dependent are at risk of complications due to ironoverload and rigorous chelation therapy is indicated. HSCT is mainly utilizedin severe DBA cases and those with secondary myelodysplastic syndrome, yetrecent studies suggest HSCT may also be useful to correct the hematologicalphenotype in children and is indicated in transfusion-dependent patients.

Ateam of European researchers conducted an analysis to determine survivaloutcomes in patients with DBA who underwent allogeneic HSCT. Data was collectedfrom 70 children with DBA (<18 years; 44 males) who were registered inGermany or France between 1985 and 2017.

Primary outcomes included engraftment, cumulative incidence of acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD), probability of overall survival (pOS), and the probability of cGVHD-free survival (cGFS).

Medianage at HSCT was 5.5 years, and 26% of patients were aged 10 years or younger atthe time of transplantation. A large number of transplantations (64%) wereperformed from an MSD and most procedures were performed after 1999 (73%). Allpatients achieved primary engraftment.

Thecumulative incidence of grade 2 to grade 4 and grade 3 to grade 4 aGVHD was 24%and 7%, respectively. Furthermore, the cumulative incidence of cGVHD was 11%. Nosignificant difference in the incidence of aGVHD comparing MSD and UD HSCT wasobserved. Over time, the probability of cGFS (87%) significantly improved from68% in years earlier than 2000 compared with 94% in 2000 and later (P <.01). cGFS was comparable forpatients who received a transplant from either a MSD or an unrelated donor(UD). However, after 1999, no severe cGVHD or deaths were reported followingMSD-HSCT, whereas the cGFS for 24 patients transplanted from an UD was 87%. Thechange of cGFS in patients transplanted at a younger age compared with olderpatients (<10 years: 90% vs 10-18 years: 78%) was not statisticallysignificant.

Studylimitations included the inability to fully analyze the role of ATG and ATGdosing due to the retrospective nature of the study, the lack of availabilityof genetic testing for all of the patients, and the small sample size ofpatients between the ages of 10 to 18 years.

In summary,these data indicate that HSCT is efficient and safe in young DBA patients and should be considered ifa MSD or matched UD is available. HSCT for transfusion dependency only must becritically discussed in older patients, the authors concluded.

Reference

Strahm B, Loewecke F, Niemeyer CM, et al. Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia. Blood Adv. 2020;4(8):17601769.

See the original post:
Outcomes of Hematopoietic Stem Cell Transplantation in Children With Diamond-Blackfan Anemia - Hematology Advisor

The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows – Benzinga

Biotech stocks had another up week, with the American Society of Gene & Stem Cell Therapy virtual conference presentations and the ASCO abstracts made available onlineThursday calling the shots. Earnings news flow continued to taper.

Biopharma companies working on vaccines/therapies for COVID-19 continued to provide updates. Novavax, Inc. (NASDAQ: NVAX) shares more than doubled, thanks to an announcement concerning a $384 million grant from the Coalition for Epidemic Preparedness Innovations.

Here are the key catalysts for the unfolding week.

The FDA is due to rule on Aquestive Therapeutics Inc's (NASDAQ: AQST) NDA for apomorphine sublingual film (APL-130277), which is being evaluated for treating off episodes in Parkinson's disease patients. APL-130277 is being developed by Sunovion Pharmaceuticals, a subsidiary of Sumitomo Dainippon Pharma, in partnership with Aquestive.

Entera Bio Ltd (NASDAQ: ENTX) is scheduled to report on Thursday interim three-month top-line biomarker data for the first 50% of the patients enrolled in the Phase 2 osteoporosis clinical trial of EB613.

Oncolytics Biotech, Inc. (NASDAQ: ONCY) is due to present at the ESMO Breast Cancer Conference, interim biomarker data from the AWARE-1 early-stage breast cancer study that is evaluating its pelareorep along with Roche Holdings AG's(OTC: RHHBY) Tecentriq.

See Also: Results From Oxford University's Human Trial Of Coronavirus Vaccine Could Arrive In June; Where Inovio, Moderna Stand

Monday

Milestone Scientific Inc. (NYSE: MLSS) (before the market open)Adamis Pharmaceuticals Corp (NASDAQ: ADMP) (after the close)

Tuesday

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (after the close)Ascendis Pharma A/S (NASDAQ: ASND) (after the close)

Wednesday

Mediwound Ltd (NASDAQ: MDWD) (before the market open)China Biologic Products Holdings Inc (NASDAQ: CBPO) (after the close)

Thursday

Entera Bio (before the market open)Medtronic PLC (NYSE: MDT) (before the market open)PAVmed Inc (NASDAQ: PAVM) (after the close)Xenon Pharmaceuticals Inc (NASDAQ: XENE) (after the close)

ORIC Pharmaceuticals Inc (NASDAQ: ORIC)

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read more:
The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows - Benzinga

Venetoclax May Play Role as Salvage Therapy in Multiply Relapsed MCL – Targeted Oncology

Venetoclax (Venclexta) resistance is primarily associated with non-BCL2 gene mutations in patients with mantle cell lymphoma (MCL), according to a study published in American Journal of Hematology. The analysis also demonstrated that venetoclax could play a potential role as salvage therapy among patients with MCL with multiple relapses.

This is the first report on the genomic profile of patients with venetoclax-resistant MCL, demonstrating that the acquisition of BCL2 mutations was infrequent and acquisition of TP53, SMARCA4, CELSR3, CCND1, andKMT2D alterations may play a role in disease progression on venetoclax therapy.

Furthermore, in our cohort of venetoclax combined with other agents, the PFS was longer compared to single-agent (8.3 vs 3.5 months), therefore we hypothesize that combination of venetoclax with other agents are promising compared to single-agent venetoclax, however randomized clinical trials would confirm whether venetoclax should be used as single-agent or in combination with other agents in relapsed patients with MCL, wrote lead author Shuangtao Zhao, MD, PhD, assistant professor, Genomic Medicine, The University of Texas MD Anderson Cancer Center.

The objective response rate (ORR) with venetoclax was 50% (12 of 24), and 21% had a complete response (CR; 5 of 24). Partial responses (PRs) were observed in 29% of patients (7 of 24), and 4 patients were not evaluable for response. Six patients were primary refractory and 2 had stable disease (SD).

The ORR was not significantly different between venetoclax monotherapy (42%) and combination (58%). The median duration of best response was 4 months (range, 1-16).

After a median follow-up of 17 months, the median progression-free survival (PFS) was 8 months, and the median overall survival (OS) was 13.5 months. The duration of response among those who had a CR was 8.6 months versus 4 months in those who had a PR (P =.58).

At the time of the last follow-up, 9 patients remained alive, 15 had died and 16 progressed. The median survival post-venetoclax treatment was 7.3 months.

Nine patients received subsequent therapy, and 4 responded, which included 1 CR after rituximab, mesna, Ifosfamide, mitoxantrone, and etoposide (R-MINE); and 3 PRs, 1 from umbralisib (TGR-1202), 1 from acalabrutinib (Calquence), and 1 from local radiation followed by R-HCVAD chemotherapy. All 4 responders were refractory to the BTK inhibitor (BTKi) ibrutinib (Imbruvica) prior to venetoclax treatment. Additionally, 2 patients had SD, and 3 did not respond to subsequent therapy.

Five patients had paired samples from whole exome sequencing (WES) before and after progression on venetoclax. Two of these patients had a CR (patients 1 and 2), 2 had a PR (patients 4 and 6), and 1 had SD (patient 7). Overall, investigators conducted WES in 12 samples, including these patients.

Patient 1 received single-agent venetoclax following 6 prior lines of therapy, and upon progression on venetoclax, the patient received R-MINE chemoimmunotherapy for 5 cycles and achieved a CR that was lost to follow-up. Patient 2 received venetoclax in combination with acalabrutinib, obinutuzumab (Gazyva), and radiation after 5 prior lines of therapy, which included an allogeneic stem cell transplant and did not receive further therapy after venetoclax.

Patient 4 received venetoclax plus obinutuzumab after 4 prior lines of therapy and received single-agent lenalidomide (Revlimid) plus bortezomib (Velcade) without response. Patient 6 had received venetoclax plus rituximab after 6 prior lines of therapy and received 7 subsequent lines of therapy after progression on the combination regimen. The patient ultimately progressed after receiving an experimental anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which was rechallenged with venetoclax/obinutuzumab/ibrutinib, obinutuzumab plus MINE, gemcitabine/oxaliplatin/obinutuzumab, acalabrutinib, R-HCVAD, and bendamustine/rituximab. Patient 7, who had 7 prior lines of therapy, received venetoclax in combination with obinutuzumab plus acalabrutinib, and was treated with 2 lines of subsequent therapy following progression on the venetoclax combination, including abemaciclib (Verzenio) and copanlisib (Aliqopa), which induced a PR before subsequently progressing.

All 5 patients had received prior ibrutinib before receiving the venetoclax treatment. Patients 1 and 2 had transformed MCL, and patients 6 and 7 had blastoid morphology MCL.

Alteration frequencies of certain genes increased by > 2-fold at progression, including TP53 (83% vs. 33%), KMT2D (67% vs. 17%), CELSR3 (67% vs. 17%), CCND1 (67% vs. 17%), KMT2C (50% vs. 17%), and ATM(50% vs. 17%). CDKN2A (67%) and NOTCH2 (50%) were increased at progression as well. A BCL2 mutation was observed in 33% of patients at progression. SMARCA4 mutations were only detected after progression.

Predominant genetic alterations at progression were observed in patient 1 (TP52, NOTCH2), patient 2 (CDKN2A, CCND1, KMT2C, and SMARCA4), patient 4 (TP53, NSD2), patient 6 (TP53, KMT2D, ATM, Bcl2,and NOTCH1) and patient 7 (TP53, CDKN2A, KMT2D, CELSR3, SMARCA4, CCND1 and gain of Bcl2). An increase in tumor mutational burden was also observed, as well as predominance of mutation signature 5 at progression.

Clonal and sub-clonal evolution of mutations associated with clinical venetoclax resistance were demonstrated in patients 2 and 7. Investigators also noted a high degree of intra-tumoral heterogeneity and treatment-induced clonal evolution as resistance.

All 5 patients had expanded TP53, SMARCA4, CELSR3, KMT2D, and KMT2C mutations at progression. Acquired DNA copy number changes were also observed in patients 2 and 7 at progression, including loss of 9p (CDKN2A) and 17p (TP53), and gain of 11p (CCND1). In patient 7, investigators noted an alteration in chromosome 18q21 depicting BCL2 mutation at progression.

The degree of aneuploidy was significantly higher among patients at progression and was noteworthy for copy number gain on chromosomes 2, 3, 4, 12, and 18, and deletion was noted at chromosome 15.

For this analysis, data were collected from 24 patients with MCL who were treated with venetoclax salvage therapy, either alone or in combination. Twelve patients received venetoclax as monotherapy, and venetoclax was given in combination with either obinutuzumab in 8 patients, a BTKi with/without obinutuzumab in 3 patients, and chemotherapy in 1 patient. The patients in this study were heavily pretreated.

Our study demonstrates that venetoclax is a potential salvage therapy in multiply relapsed patients with MCL. The majority (92%) patients in this study were exposed to BTKi, 66% were BTKi refractory, and these patients exhibited poor outcomes, wrote Zhao.

Reference

Zhao S, Kanagal-Shamanna R, Navsaria L, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) outcomes and mutation profile from venetoclax resistant MCL patients [Published Online April 2, 2020].American Journal of Hematology. DOI: 10.1002/ajh.25796.

Excerpt from:
Venetoclax May Play Role as Salvage Therapy in Multiply Relapsed MCL - Targeted Oncology

GEMoaB Announces Data Presentations Supporting Key Features of Its UniCAR Platform At the Upcoming American Association for Cancer Research (AACR)…

DRESDEN, Germany, May 15, 2020 /PRNewswire/ -- GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced acceptance of three presentations on pre-clinical data for its proprietary universal CAR-T platform (UniCAR) targeting acute leukemia and solid tumors at the 2020 Virtual Annual Meeting of the American Association for Cancer Research (AACR II) being held from June 22-24.

CAR-T cell therapy holds great promise for treating a wide range of malignancies. Nevertheless, the CAR-T approach faces multiple challenges, including the risk of acute and long-term toxicities, a current lack of suitable targets, insufficient engraftment and persistence and a microenvironment hostile to CAR-T cells especially in solid tumors.

The AACR poster presentations highlight GEMoaB's rapidly switchable universal CAR-T platform, UniCAR. The UniCAR platform promises an improved therapeutic window and increased efficacy and safety over conventional CAR-T therapies in hematological malignancies and solid tumors.

"At this year's AACR meeting II, we are pleased to present important pre-clinical data from our rapidly switchable UniCAR platform," said Armin Ehninger, Ph.D., Chief Scientific Officer of GEMoaB. "Our data suggest the opportunity to actively target CD123 in acute leukemias as well as PSMA and PD-L1 in solid tumors due to UniCAR's rapid switch on/off capability. In solid tumor models, they also show potentially superior tumor penetration, expansion and persistence capabilities as well as a reduced risk of immunosuppression by the tumor microenvironment."

The data further support the ongoing clinical development of UniCAR in hematological malignancies and solid tumors. A Phase IA dose-finding study of the first UniCAR asset, UniCAR-T-CD123, for the treatment of relapsed/refractory AML and ALL is ongoing. A Phase IA study with UniCAR-T-PSMA directed against CRPC and other PSMA-expressing late-stage solid tumors will be initiated by H2 2020.

GEMoaB's poster presentations at AACR II:

AboutGEMoaB

GEMoaB is a privately-owned, clinical-stage biopharmaceutical company that isaiming to become a globally leading biopharmaceutical company. By advancing its proprietary UniCAR, RevCAR and ATAC platforms, the company will discover, develop, manufacture and commercialize next-generation immunotherapies for the treatment of cancer patients with a high unmet medical need.

GEMoaB has a broad pipeline of product candidates in pre-clinical and clinical development for the treatment of hematological malignancies as well as solid tumors. Its clinical stage assets GEM333, an Affinity-Tailored Adaptor for T-Cells (ATAC) with binding specificity to CD33 in relapsed/refractory AML, and GEM3PSCA, an ATAC with binding specificity to PSCA for the treatment of castrate-resistant metastatic prostate cancer and other PSCA expressing late stage solid tumors, are currently investigated in Phase I studies and globally partnered with Bristol-Myers Squibb. A Phase IA dose-finding study of the first UniCAR asset, UniCAR-T-CD123 for treatment of relapsed/refractory AML and ALL is ongoing, UniCAR-T-PSMA against CRPC and other PSMA-expressing late-stage solid tumors, is planned to be tested in a Phase IA study initiated by H2 2020.

Manufacturing expertise, capability and capacity are key for developing cellular immunotherapies for cancer patients. GEMoaB has established a preferred partnership with its sister company Cellex, a world leader in manufacturing hematopoietic blood stem cell products and a leading European CMO for CAR-T cells, co-operating in that area with several large biotech companies.

About UniCAR

GEMoaB is developing a rapidly switchable universal CAR-T platform, UniCAR, to improve the therapeutic window and increase efficacy and safety of CAR-T cell therapies in more challenging cancers, including solid tumors. Standard CAR-T cells depend on the presence and direct binding of cancer antigens for activation and proliferation. An inherent key feature of the UniCAR platform is a rapidly switchable on/off mechanism (less than 4 hours after interruption of TM supply) enabled by the short pharmacokinetic half-life and fast internalization of soluble adaptors termed targeting modules (TMs). These TMs provide the antigen-specificity to activate UniCAR gene-modified T-cells (UniCAR-T) and consist of a highly flexible antigen-binding moiety, linked to a small peptide motif recognized by UniCAR-T.

About ATAC

GEMoaB's platform of Affinity-Tailored Adaptors for T-Cells (ATAC) is characterized by high binding affinity to tumor antigens and lower affinity to the CD3 antigen on effector T-cells, preventing T-cell auto-activation in pre-clinical models. Safety and tolerability of the treatment are also increased by the relatively short serum half-life (60 min). The use of fully humanized antibodies reduces the risk of immunogenicity even in case of chronic dosing. Half-life extended ATACs are in pre-clinical development.

More information can be found at http://www.gemoab.com.

Forward-looking Statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results and matters discussed in the forward looking statements. Forward looking statements include statements concerning our plans, goals, future events and or other information that is not historical information.

The Company does not assume any liability whatsoever for forward-looking statements. The Company assumes that potential partners will perform and rely on their own independent analyses as the case may be. The Company will be under no obligation to update the Information.

Logo - https://mma.prnewswire.com/media/947610/GEMoaB_Logo.jpg

For further information please contact:Constanze Medack c.medack@gemoab.com; Tel.: +49 351-4466-45027

Investor Contact:Michael Pehl m.pehl@gemoab.com Tel.: +49 351-4466-45030

Read more:
GEMoaB Announces Data Presentations Supporting Key Features of Its UniCAR Platform At the Upcoming American Association for Cancer Research (AACR)...